Medicenna Historical Income Statement

MDNA Stock

CAD 1.88 0.08 4.08%

Historical analysis of Medicenna Therapeutics income statement accounts such as Total Revenue of 0.0 can show how well Medicenna Therapeutics Corp performed in making a profits. Evaluating Medicenna Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Medicenna Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Medicenna Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Medicenna Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medicenna Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Medicenna Income Statement Analysis

Medicenna Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Medicenna Therapeutics shareholders. The income statement also shows Medicenna investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Medicenna Therapeutics Income Statement Chart

At this time, Medicenna Therapeutics' Interest Expense is very stable compared to the past year. As of the 11th of December 2024, Net Interest Income is likely to grow to about 1.3 M, while Depreciation And Amortization is likely to drop 4,275.

Other Operating Expenses Operating Income Research Development

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Medicenna Therapeutics. It is also known as Medicenna Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from Medicenna Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Medicenna Therapeutics Corp is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most accounts from Medicenna Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Medicenna Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Medicenna Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Interest Income	69K	6.3M	1.2M	1.2M
Net Interest Income	69K	914K	1.2M	1.3M

Interest Income Net Interest Income

Medicenna Therapeutics income statement Correlations

	Depreciation And Amortization	Interest Expense	Selling General Administrative	Gross Profit	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Net Interest Income	Interest Income	Reconciled Depreciation	Selling And Marketing Expenses
Depreciation And Amortization		-0.31	-0.6	0.37	-0.57	0.57	0.54	0.58	-0.55	0.61	-0.38	-0.57	0.54	-0.1	0.46	0.31	-0.33	-0.23	-0.11	0.23
Interest Expense	-0.31		0.56	0.14	0.5	-0.67	-0.65	-0.6	0.46	-0.6	-0.12	0.5	-0.65	-0.4	-0.48	-0.99	0.98	0.67	-0.36	-0.79
Selling General Administrative	-0.6	0.56		-0.65	0.99	-0.96	-0.87	-0.96	0.97	-0.96	0.67	0.99	-0.87	-0.07	-0.73	-0.58	0.61	0.47	0.4	-0.3
Gross Profit	0.37	0.14	-0.65		-0.72	0.61	0.57	0.68	-0.75	0.68	-1.0	-0.72	0.57	-0.08	0.57	-0.14	0.02	0.09	-0.93	-0.11
Other Operating Expenses	-0.57	0.5	0.99	-0.72		-0.96	-0.89	-0.97	1.0	-0.97	0.73	1.0	-0.89	-0.1	-0.76	-0.51	0.56	0.4	0.49	-0.28
Operating Income	0.57	-0.67	-0.96	0.61	-0.96		0.91	0.99	-0.95	0.99	-0.62	-0.96	0.91	0.13	0.75	0.68	-0.71	-0.54	-0.35	0.45
Net Income From Continuing Ops	0.54	-0.65	-0.87	0.57	-0.89	0.91		0.95	-0.89	0.95	-0.59	-0.89	1.0	0.45	0.95	0.6	-0.72	-0.22	-0.34	0.66
Ebit	0.58	-0.6	-0.96	0.68	-0.97	0.99	0.95		-0.97	1.0	-0.69	-0.97	0.95	0.19	0.83	0.59	-0.66	-0.41	-0.43	0.46
Research Development	-0.55	0.46	0.97	-0.75	1.0	-0.95	-0.89	-0.97		-0.97	0.77	1.0	-0.89	-0.1	-0.78	-0.46	0.52	0.35	0.53	-0.27
Ebitda	0.61	-0.6	-0.96	0.68	-0.97	0.99	0.95	1.0	-0.97		-0.69	-0.97	0.95	0.18	0.82	0.59	-0.66	-0.41	-0.42	0.46
Cost Of Revenue	-0.38	-0.12	0.67	-1.0	0.73	-0.62	-0.59	-0.69	0.77	-0.69		0.73	-0.59	0.06	-0.59	0.12	0.0	-0.08	0.93	0.09
Total Operating Expenses	-0.57	0.5	0.99	-0.72	1.0	-0.96	-0.89	-0.97	1.0	-0.97	0.73		-0.89	-0.1	-0.76	-0.51	0.56	0.4	0.49	-0.28
Income Before Tax	0.54	-0.65	-0.87	0.57	-0.89	0.91	1.0	0.95	-0.89	0.95	-0.59	-0.89		0.45	0.95	0.6	-0.72	-0.22	-0.34	0.66
Total Other Income Expense Net	-0.1	-0.4	-0.07	-0.08	-0.1	0.13	0.45	0.19	-0.1	0.18	0.06	-0.1	0.45		0.59	0.28	-0.47	0.31	0.05	0.71
Net Income	0.46	-0.48	-0.73	0.57	-0.76	0.75	0.95	0.83	-0.78	0.82	-0.59	-0.76	0.95	0.59		0.39	-0.57	0.09	-0.39	0.66
Income Tax Expense	0.31	-0.99	-0.58	-0.14	-0.51	0.68	0.6	0.59	-0.46	0.59	0.12	-0.51	0.6	0.28	0.39		-0.96	-0.78	0.37	0.69
Net Interest Income	-0.33	0.98	0.61	0.02	0.56	-0.71	-0.72	-0.66	0.52	-0.66	0.0	0.56	-0.72	-0.47	-0.57	-0.96		0.61	-0.24	-0.82
Interest Income	-0.23	0.67	0.47	0.09	0.4	-0.54	-0.22	-0.41	0.35	-0.41	-0.08	0.4	-0.22	0.31	0.09	-0.78	0.61		-0.26	-0.14
Reconciled Depreciation	-0.11	-0.36	0.4	-0.93	0.49	-0.35	-0.34	-0.43	0.53	-0.42	0.93	0.49	-0.34	0.05	-0.39	0.37	-0.24	-0.26		0.27
Selling And Marketing Expenses	0.23	-0.79	-0.3	-0.11	-0.28	0.45	0.66	0.46	-0.27	0.46	0.09	-0.28	0.66	0.71	0.66	0.69	-0.82	-0.14	0.27

Click cells to compare fundamentals

Medicenna Therapeutics Account Relationship Matchups

Medicenna Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	7.9K	40K	38K	5K	4.5K	4.3K
Selling General Administrative	2.5M	6.5M	7.7M	7.0M	7.9M	4.2M
Gross Profit	(7.9K)	(40K)	(38K)	(5K)	(4.5K)	(4.7K)
Other Operating Expenses	8.2M	17.4M	22.5M	16.3M	19.7M	10.7M
Operating Income	(8.2M)	(17.2M)	(22.3M)	(21.6M)	(19.7M)	(18.7M)
Net Income From Continuing Ops	(8.3M)	(17.3M)	(22.6M)	(10.0M)	(25.5M)	(24.2M)
Ebit	(8.3M)	(17.3M)	(22.6M)	(16.3M)	(18.7M)	(17.7M)
Research Development	5.9M	10.9M	14.7M	9.3M	11.8M	6.7M
Ebitda	(8.3M)	(17.2M)	(22.5M)	(16.3M)	(18.7M)	(17.7M)
Cost Of Revenue	7.9K	40K	38K	5K	5.8K	5.5K
Total Operating Expenses	8.2M	17.4M	22.5M	16.3M	19.7M	10.7M
Income Before Tax	(8.3M)	(17.3M)	(22.6M)	(10.0M)	(25.5M)	(24.2M)
Total Other Income Expense Net	919K	106K	1.6M	7.0M	(5.8M)	(5.5M)
Net Income Applicable To Common Shares	(8.3M)	(17.3M)	(22.6M)	(10.0M)	(9.0M)	(9.5M)
Net Income	(8.3M)	(17.2M)	(22.6M)	1.5M	(25.5M)	(24.2M)
Income Tax Expense	32.3K	(106K)	69K	(11.6M)	(10.4M)	(9.9M)
Net Interest Income	6.7K	314K	69K	914K	1.2M	1.3M
Interest Income	32.3K	106K	69K	6.3M	1.2M	1.2M
Reconciled Depreciation	7.9K	40K	38K	4K	4.6K	4.4K

Pair Trading with Medicenna Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medicenna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medicenna Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Medicenna Stock

0.62	BNS	Bank of Nova Scotia	Pair Corr
0.43	RY-PS	Royal Bank	Pair Corr
0.39	TD-PFI	Toronto Dominion Bank	Pair Corr
0.36	RY-PM	Royal Bank	Pair Corr
0.31	RY	Royal Bank	Pair Corr

The ability to find closely correlated positions to Medicenna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medicenna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medicenna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medicenna Therapeutics Corp to buy it.

The correlation of Medicenna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medicenna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medicenna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Medicenna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Medicenna Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Medicenna Historical Income Statement

About Medicenna Income Statement Analysis

Medicenna Therapeutics Income Statement Chart

Other Operating Expenses

Operating Income

Medicenna Therapeutics income statement Correlations

Medicenna Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Medicenna Therapeutics income statement Accounts

Pair Trading with Medicenna Therapeutics

Moving against Medicenna Stock

Other Information on Investing in Medicenna Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Ebitda	+ 1.0	Ebit
Total Operating Expenses	+ 1.0	Research Development
Other Operating Expenses	+ 0.99	Selling General Administrative

Cost Of Revenue	- 1.0	Gross Profit
Income Tax Expense	- 0.99	Interest Expense
Total Operating Expenses	- 0.97	Ebitda
Ebitda	- 0.97	Research Development
Total Operating Expenses	- 0.97	Ebit
Research Development	- 0.97	Ebit